Another ViewEPS of 49c beat estimates of 47.9c; revenue of $2.36B beat estimates of $2.29B. EBITDA of $202.7M matched estimates. BMO raised it to 'outperform' and two other brokers raised target prices. The backlog is at a record ($15.6B) and the nuclear division saw 42% growth, and was well ahead of forecast with 30% organic growth. The quarter was fine and the outlook we think has improved. Most of its previous 'issues' seem to have been resolved and we would be OK buying ATRL. (5iResearch)